Page last updated: 2024-11-11

bicyclol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bicyclol: an antihepatitis drug, on the metabolism and hepatotoxicity of aflatoxin B1 (AFB1) in rats. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9821754
CHEMBL ID482035
SCHEMBL ID9600725
MeSH IDM0454685

Synonyms (26)

Synonym
bicyclol
6-methoxycarbonyl-6'-hydroxymethyl-2,3,2',3'-bis(methylenedioxy)-4,4'-dimethoxybiphenyl
4,4'-bi-(1,3-benzodioxole)-5-carboxylic acid, 5'-(hydroxymethyl)-7,7'-dimethoxy-, methyl ester
CHEMBL482035
methyl 5'-(hydroxymethyl)-7,7'-dimethoxy-[4,4'-bibenzo[d][1,3]dioxole]-5-carboxylate
118159-48-1
AKOS016007877
unii-9734122th2
4,4'-bi-1,3-benzodioxole)-5-carboxylic acid, 5'-(hydroxymethyl)-7,7'-dimethoxy-, methyl ester
9734122th2 ,
sy 801
bicyclol [who-dd]
S6453
HY-B0766
SCHEMBL9600725
DTXSID30152026
J-003718
bicyclol, >=98% (hplc)
methyl 4-[5-(hydroxymethyl)-7-methoxy-1,3-benzodioxol-4-yl]-7-methoxy-1,3-benzodioxole-5-carboxylate
BCP25554
AS-16866
sy801
Q27271958
F85022
5'-(hydroxymethyl)-7,7'-dimethoxy-[4,4'-bi-1,3-benzodioxole]-5-carboxylic acid, methyl ester
NCGC00408803-01

Research Excerpts

Overview

Bicyclol is a new synthetic anti-hepatitic drug and primarily metabolized by CYP3A. It is a novel synthetic drug for the treatment of chronic viral hepatitis in China.

ExcerptReferenceRelevance
"Bicyclol is a potential candidate for DILI."( Bicyclol for the treatment of drug-induced liver injury: a propensity score matching analysis using a nationwide inpatient database.
Chen, C; Han, X; Lai, R; Mao, Y; Shang, J; Tang, J; Wang, Y; Xu, Q; Zhang, X; Zhong, W; Zong, P, 2021
)
3.51
"Bicyclol is a new synthetic anti-hepatitic drug and primarily metabolized by CYP3A. "( Evaluation of pharmacokinetic interactions between bicyclol and co-administered drugs in rat and human liver microsomes in vitro and in rats in vivo.
Hu, J; Li, Y; Yang, S; Zhao, Z, 2019
)
2.21
"Bicyclol is a synthetic compound known to protect the liver against oxidation and lipid injuries."( Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose.
Ding, XD; Fan, JG; Han, Y; Ma, AL; Shi, JP; Xu, Y, 2014
)
1.39
"Bicyclol is a novel anti-hepatitis drug."( Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human.
Chen, H; Hu, J; Li, D; Li, Y; Liu, Z; Sheng, L; Wang, B; Yang, S, 2015
)
1.35
"Bicyclol is a novel hepatoprotectant that has been shown to protect against liver injury by inducing Hsps, including Hsp27 and Hsp70."( Induction of heat shock protein 27 by bicyclol attenuates d-galactosamine/lipopolysaccharide-induced liver injury.
Dai, HJ; Ding, X; Huang, XD; Li, DW; Lu, YX; Song, YG; Sun, AJ; Wang, YX; Zhang, M, 2016
)
1.43
"Bicyclol is a synthetic antihepatitis drug with antioxidative property. "( Effects of bicyclol on liver regeneration after partial hepatectomy in rats.
Li, Y; Yao, XM; Zhao, J, 2009
)
2.19
"Bicyclol is a novel anti-hepatitis drug used for the treatment of chronic hepatitis B. "( Preparation and evaluation of bicyclol microemulsions for enhanced oral bioavailability.
Ryu, JK; Yoo, SD, 2012
)
2.11
"Bicyclol is a novel synthetic drug for the treatment of chronic viral hepatitis in China. "( Mechanism of protective action of bicyclol against CCl-induced liver injury in mice.
Li, Y; Liu, GT; Wei, HL; Xu, JY; Yu, LH; Zhang, H, 2005
)
2.05
"Bicyclol is a novel synthetic 'anti-hepatitis' drug, used in China for chronic hepatitis B. "( Bicyclol for chronic hepatitis B.
Hao, B; Liu, G; Roger, H; Wu, T; Xie, L, 2006
)
3.22
"Bicyclol is a novel synthetic 'anti-hepatitis' drug, used in China for chronic hepatitis C. "( Bicyclol for chronic hepatitis C.
Liu, GJ; Wu, TX; Yang, XY; Zhuo, Q, 2007
)
3.23
"Bicyclol is a new generation of anti-hepatitis drug with China's own intellectual property rights. "( [Synthesis of metabolites of bicyclol].
Hu, W; Li, Y; Tang, Y; Zhang, CZ, 2007
)
2.07
"Bicyclol is a novel synthetic anti-hepatitis drug with anti-oxidative and anti-inflammatory property."( Protective effect of bicyclol on acute alcohol-induced liver injury in mice.
Chen, H; Li, Y; Zhao, J, 2008
)
1.39

Effects

Bicyclol has been approved as an anti-inflammatory, hepatoprotective drug in China to treat various forms of hepatitis. It still has the problems of low solubility and bioavailability.

ExcerptReferenceRelevance
"Bicyclol (BIC) has been widely used to treat drug-induced liver injury (DILI), however, it still has the problems of low solubility and bioavailability. "( Identification of bicyclol metabolites in rat plasma, urine and feces by UPLC-Q-TOF-MS/MS and evaluation of the efficacy and safety of these metabolites based on network pharmacology and molecular docking combined with toxicity prediction.
Fan, G; Huang, X; Jia, M; Jiang, X; Li, X; Liu, Y; Lou, Y; Tang, Y; Wang, S; Wu, Z, 2022
)
2.5
"Bicyclol has been approved as an anti-inflammatory, hepatoprotective drug in China to treat various forms of hepatitis. "( Bicyclol ameliorates nonalcoholic fatty liver disease in mice via inhibiting MAPKs and NF-κB signaling pathways.
Chen, G; Liang, G; Wang, M; Wang, Y; Wang, Z; Xiao, Z; Xu, M; Yan, Y; Yang, D; Zhao, W; Zhuang, Z, 2021
)
3.51
"Bicyclol has been proved to elicit a series of biologic effects through its anti-inflammatory property in treating hepatitis and hepatic ischemic/reperfusion injury."( Neuroprotective effect of bicyclol in rat ischemic stroke: down-regulates TLR4, TLR9, TRAF6, NF-κB, MMP-9 and up-regulates claudin-5 expression.
Bai, X; Chen, L; Cui, L; Fu, B; Wang, L; Zhang, J; Zhang, L; Zhang, X; Zhao, X; Zhu, C, 2013
)
1.41
"Bicyclol has been proved to elicit a variety of biological effects through its antioxidant and anti-inflammatory properties."( Bicyclol upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia.
Bai, X; Chen, L; Cui, L; Fu, B; Wang, L; Wang, X; Zhang, J; Zhang, L; Zhang, X; Zhao, T; Zhao, X; Zhao, Y; Zhu, C, 2014
)
2.57

Actions

Bicyclol may suppress the apoptosis of alveolar epithelial cells by upregulating miR-455-3p. Bicyclo can inhibit the decrease of CYP3A1/2 activity, and up-regulate the mRNA and protein expressions of CYCPs.

ExcerptReferenceRelevance
"Bicyclol may suppress the apoptosis of alveolar epithelial cells by upregulating miR-455-3p."( Protective effect of bicyclol against pulmonary fibrosis via regulation of microRNA-455-3p in rats.
Chai, X; Zhou, Y, 2020
)
1.6
"Bicyclol can inhibit the decrease of CYP3A1/2 activity, and up-regulate the mRNA and protein expressions of CYP3A1 and CYP2E1."( Effects of bicyclol on the activity and expression of CYP450 enzymes of rats after partial hepatectomy.
Gu, Y; Li, Y; Wang, BL; Yao, XM, 2011
)
1.48

Treatment

Bicyclol pretreatment significantly improved LPS-induced lung pathological changes, inhibited myeloperoxidase (MPO) activity, and reduced lung/body and lung wet/dry weight ratios. Treatment with bicyclol significantly reduced liver fibrosis and bile duct proliferation after BDL.

ExcerptReferenceRelevance
"Bicyclol pretreatment inhibited the changes in mRNA levels of CYP450 isozymes (including the increase in CYP2a5 and decrease in CYP2b10, 2c29, 2c37, 3a11, and 7b1)."( Effects of bicyclol on hepatic sinusoidal obstruction syndrome induced by Gynura segetum.
Jia, S; Li, H; Shao, J; Wu, J; Xu, Z; Yao, J; Yao, X; Zhang, H; Zhang, X, 2022
)
1.83
"Bicyclol treatment stimulated HSF1 activation and increased the HSF1-HSE binding activity (the maximal response: 2.1 fold increase at 100 micromol/L)."( Bicyclol protects HepG2 cells against D-galactosamine-induced apoptosis through inducing heat shock protein 27 and mitochondria associated pathway.
Bao, XQ; Liu, GT, 2010
)
2.52
"Bicyclol pretreatment significantly improved LPS-induced lung pathological changes, inhibited myeloperoxidase (MPO) activity, and reduced lung/body and lung wet/dry weight ratios."( Protective effect of bicyclol on lipopolysaccharide-induced acute lung injury in mice.
Dong, MQ; Li, ZC; Liu, Y; Luo, Y; Xu, DQ; Zhang, B; Zhao, PT, 2011
)
1.41
"Bicyclol pretreatment slightly increased the production of the less toxic metabolite aflatoxin Q1."( Effects of bicyclol on aflatoxin B1 metabolism and hepatotoxicity in rats.
Li, Y; Lu, H, 2002
)
1.43
"Bicyclol treatment for 7 days decreased hepatic triglyceride (5-76%) and total cholesterol (5-48%) levels in mice fed with high-fat/cholesterol diet."( Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice.
Dong, H; Fong, WF; Ko, KM; Pan, SY; Wang, H; Xiang, CJ; Yu, ZL; Zhao, XY, 2007
)
2.5
"Treatment with bicyclol significantly reduced liver fibrosis and bile duct proliferation after BDL. "( Protective effect of bicyclol against bile duct ligation-induced hepatic fibrosis in rats.
Hao, XF; He, HW; Li, NR; Shao, RG; Zhang, GL; Zhao, SS; Zhen, YZ, 2015
)
1.09
"Pretreatment with bicyclol showed a marked reduction in the above condition."( A novel antihepatitis drug, bicyclol, prevents liver carcinogenesis in diethylnitrosamine-initiated and phenobarbital-promoted mice tumor model.
Liu, G; Sun, H; Wei, H; Yu, L, 2012
)
1
"Pretreatment with bicyclol (300 mg/kg) also lowered the mortality after LPS/GalN intoxication."( Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice.
Li, Y; Wang, H, 2006
)
0.98
"The treatment with bicyclol markedly reduced all the above criteria."( Effects of bicyclol on dimethylnitrosamine-induced liver fibrosis in mice and its mechanism of action.
Hu, QW; Liu, GT, 2006
)
1.04

Toxicity

Bicyclol (25 and 50 mg TID) appeared efficacious and safe for treating idiosyncratic acute DILI. Bicycloline pretreatment slightly increased the production of the less toxic metabolite aflatoxin Q1.

ExcerptReferenceRelevance
" Bicyclol pretreatment slightly increased the production of the less toxic metabolite aflatoxin Q1."( Effects of bicyclol on aflatoxin B1 metabolism and hepatotoxicity in rats.
Li, Y; Lu, H, 2002
)
1.61
" (4) Both groups had no significant adverse events."( [Study on treatment effectiveness and safety in children with chronic hepatitis B or C using bicyclo tablets].
Chen, DW; Dong, Y; Gan, Y; Jia, WZ; Tang, HM; Wang, LM; Xu, ZQ; Yang, XJ; Zhang, HF; Zhu, SS, 2005
)
0.33
" No obvious adverse events which were probably related to the drugs were observed in this study."( [Effectiveness and safety of bicyclol combined with thymosin in treatment of chronic viral hepatitis B].
Gu, XJ; Hou, SR; Qiu, J; Xie, BH; Yan, XM, 2007
)
0.63
" The incidence rates of adverse events between two groups were not statistically significant."( [The clinical efficacy and safety of adefovir dipivoxil in combination with bicyclol for the treatment of senior patients with chronic hepatitis B].
Cai, SP; Fan, ZP; He, WP; Ji, YJ; Zhang, WJ, 2011
)
0.6
" Adverse events, serious adverse events and adverse drug reactions were similar across groups."( Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial.
Chen, C; Chen, J; Chen, Y; Chu, N; Gu, J; Hu, P; Lan, P; Li, D; Li, J; Li, L; Li, Y; Mao, Y; Mei, Z; Shang, J; Tang, J; Wang, C; Wang, X; Wang, Y; Xie, Q; Xie, W; Xue, D; Yang, C; Zhao, L, 2022
)
1.03
"Bicyclol (25 and 50 mg TID) appeared efficacious and safe for treating idiosyncratic acute DILI, while bicyclol 50 mg TID showed higher efficacy."( Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial.
Chen, C; Chen, J; Chen, Y; Chu, N; Gu, J; Hu, P; Lan, P; Li, D; Li, J; Li, L; Li, Y; Mao, Y; Mei, Z; Shang, J; Tang, J; Wang, C; Wang, X; Wang, Y; Xie, Q; Xie, W; Xue, D; Yang, C; Zhao, L, 2022
)
2.47

Pharmacokinetics

ExcerptReferenceRelevance
"Physiologically based pharmacokinetic (PBPK) modeling can assist in formulation development."( Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human.
Chen, H; Hu, J; Li, D; Li, Y; Liu, Z; Sheng, L; Wang, B; Yang, S, 2015
)
0.63
" The aim of this study was to evaluate the pharmacokinetic interactions between bicyclol and co-administered drugs including metformin, pioglitazone, atorvastatin, fenofibrate, Cyclosporin A (CsA), and tacrolimus in rat and human liver microsomes (RLMs/HLMs) in vitro and in rats in vivo."( Evaluation of pharmacokinetic interactions between bicyclol and co-administered drugs in rat and human liver microsomes in vitro and in rats in vivo.
Hu, J; Li, Y; Yang, S; Zhao, Z, 2019
)
0.99

Compound-Compound Interactions

Bicyclol combined with ganciclocir can reduce glutamic pyruvic transaminase, alkaline phosphatase and serum total bilirubin. The treatment of ADV in combination with bicyclol for senior patients with CHB is effective and safe.

ExcerptReferenceRelevance
"To analyze the efficacy and safety of bicyclol combined with thymosin in treatment of chronic viral hepatitis B (CHB)."( [Effectiveness and safety of bicyclol combined with thymosin in treatment of chronic viral hepatitis B].
Gu, XJ; Hou, SR; Qiu, J; Xie, BH; Yan, XM, 2007
)
0.9
"To analyze the efficacy of adefovir dipivoxil combined with bicyclol in treatment of HBeAg-positive chronic viral hepatitis B (CHB)."( [The analyse of effectiveness in HBeAg-positive chronic viral hepatitis B treated by adefovir dipivoxil combined with bicyclol].
Sheng, JF; Xiang, DR, 2009
)
0.8
"To investigate the clinical efficacy and safety of adefovir dipivoxil (ADV) in combination with bicyclol for the treatment of chronic hepatitis B (CHB) in seniors."( [The clinical efficacy and safety of adefovir dipivoxil in combination with bicyclol for the treatment of senior patients with chronic hepatitis B].
Cai, SP; Fan, ZP; He, WP; Ji, YJ; Zhang, WJ, 2011
)
0.82
"It suggested that the treatment of ADV in combination with bicyclol for senior patients with CHB is effective and safe."( [The clinical efficacy and safety of adefovir dipivoxil in combination with bicyclol for the treatment of senior patients with chronic hepatitis B].
Cai, SP; Fan, ZP; He, WP; Ji, YJ; Zhang, WJ, 2011
)
0.84
"To evaluate the therapeutic effects of bicyclol combined with ganciclocir on infantile cytomegalovirus hepatitis."( [Bicyclol combined with ganciclovir for treatment of infantile cytomegalovirus hepatitis].
Guan, HS; Jia, MY; Liang, GJ; Liu, YH; Yan, AP, 2015
)
1.6
"Bicyclol combined with ganciclocir can reduce glutamic pyruvic transaminase, alkaline phosphatase and serum total bilirubin, and decrease bile acid levels to lessen liver cell damage and promote the recovery of liver cells."( [Bicyclol combined with ganciclovir for treatment of infantile cytomegalovirus hepatitis].
Guan, HS; Jia, MY; Liang, GJ; Liu, YH; Yan, AP, 2015
)
2.77
" In addition, the efficacy and safety of BIC's metabolites were evaluated by network pharmacology and molecular docking combined with toxicity prediction."( Identification of bicyclol metabolites in rat plasma, urine and feces by UPLC-Q-TOF-MS/MS and evaluation of the efficacy and safety of these metabolites based on network pharmacology and molecular docking combined with toxicity prediction.
Fan, G; Huang, X; Jia, M; Jiang, X; Li, X; Liu, Y; Lou, Y; Tang, Y; Wang, S; Wu, Z, 2022
)
1.06

Bioavailability

Bicyclol is insoluble in water and poorly absorbed after oral administration. The poor bioavailability of bicyclol is mostly due to P-gp mediated efflux and metabolism by CYP3A in intestine.

ExcerptReferenceRelevance
"To determine the possible mechanism of poor bioavailability of bicyclol, and clarify the respective contribution of P- glycoprotein (P-gp) and Cytochrome 3A (CYP3A)."( A study of intestinal absorption of bicyclol in rats: active efflux transport and metabolism as causes of its poor bioavailability.
Chen, H; Hu, J; Li, Y; Tan, W; Zhao, J, 2008
)
0.86
"The poor bioavailability of bicyclol is mostly due to P-gp mediated efflux and metabolism by CYP3A in intestine, with CYP3A making more contribution than P-gp."( A study of intestinal absorption of bicyclol in rats: active efflux transport and metabolism as causes of its poor bioavailability.
Chen, H; Hu, J; Li, Y; Tan, W; Zhao, J, 2008
)
0.91
" Bicyclol is insoluble in water and poorly absorbed after oral administration."( Preparation and evaluation of bicyclol microemulsions for enhanced oral bioavailability.
Ryu, JK; Yoo, SD, 2012
)
1.58
"To overcome problems associated with the poor solubility and low oral bioavailability of bicyclol, a microemulsion system was prepared and evaluated in vitro and in vivo."( Preparation and evaluation of bicyclol microemulsions for enhanced oral bioavailability.
Ryu, JK; Yoo, SD, 2012
)
0.89
" These findings demonstrate that the microemulsion may be a useful drug delivery system to improve the oral bioavailability of bicyclol."( Preparation and evaluation of bicyclol microemulsions for enhanced oral bioavailability.
Ryu, JK; Yoo, SD, 2012
)
0.87

Dosage Studied

ExcerptRelevanceReference
"As a result, WLP-S-10 200 mg/kg significantly reduced liver injury induced by CCl(4) and decreased the mortality rate of mice because of acute liver failure caused by lethal dosage of acetaminophen or d-galactosamine plus LPS."( Protection by bicyclol derivatives against acetaminophen-induced acute liver failure in mice and its active mechanism.
Hou, Y; Li, L; Liu, G; Tong, Y; Wei, H; Wu, L; Wu, S, 2008
)
0.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID1525233Hepatoprotective activity against APAP-induced toxicity in human HepG2 cells assessed as cell survival rate at 10 uM after 48 hrs by MTT assay relative to control2019Journal of natural products, 05-24, Volume: 82, Issue:5
Sesquiterpenes from an Endophytic Aspergillus flavus.
AID1433214Hepatoprotective activity against APAP-induced cell injury in human HepG2 cells assessed as survival rate at 10 uM after 48 hrs by MTT assay relative to control2016Journal of natural products, 06-24, Volume: 79, Issue:6
Bioactive Sesquiterpenoid and Polyacetylene Glycosides from Atractylodes lancea.
AID1318722Hepatoprotective activity in human HepG2 cells assessed as inhibition of paracetamol-induced cell damage at 10 uM preincubated for 1 hr followed by paracetamol addition measured after 24 hrs by MTT assay relative to control2016Journal of natural products, 06-24, Volume: 79, Issue:6
Polycyclic Polyprenylated Acylphloroglucinol Congeners from Hypericum scabrum.
AID1464910Hepatoprotective activity in human HepG2 cells assessed as inhibition of paracetamol-induced reduction in cell viability at 10 uM pretreated for 1 hr followed by paracetamol addition after 24 hrs by MTT assay relative to control2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Polycyclic polyprenylated acylphloroglucinol derivatives from Hypericum scabrum.
AID1063365Hepatoprotective activity against D-galactosamine-induced toxicity in rat WB-F344 cells assessed as cell survival at 10 uM preincubated for 1 hr followed by D-galactosamine challenge measured after 24 hrs by MTT assay relative to normal cell2014Journal of natural products, Jan-24, Volume: 77, Issue:1
Chemical constituents from Inonotus obliquus and their biological activities.
AID1055749Hepatoprotective activity against D-galactosamine-induced cell toxicity in human HL-7702 cells assessed as cell survival at 10 uM incubated for 1 hr prior to D-galactosamine-challenge measured after 24 hrs by MTT assay relative to normal cells2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Hepatoprotective prenylaromadendrane-type diterpenes from the gum resin of Boswellia carterii.
AID465832Hepatoprotective activity in rat WB-F344 cells assessed as inhibition of D-galactosamine-induced cytotoxicity at 10 uM after 1 hrs by MTT assay relative to control treated before D-galactosamine challenge2010Journal of natural products, Feb-26, Volume: 73, Issue:2
Hepatoprotective constituents from the roots and stems of Erycibe hainanesis.
AID1056620Hepatoprotective activity against D-galactosamine-induced toxicity in human HL-7702 cells assessed as survival rate at 1x10'-5 M by MTT assay relative to normal cell2013Journal of natural products, Dec-27, Volume: 76, Issue:12
Dibenzoyl and isoflavonoid glycosides from Sophora flavescens: inhibition of the cytotoxic effect of D-galactosamine on human hepatocyte HL-7702.
AID706699Hepatoprotective activity in human HL7702 cells assessed as inhibition of D-galactosamine-induced cell damage at 10 uM preincubated for 1 hr prior to D-galactosamine challenge measured after 24 hrs by MTT assay relative to untreated control2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hepatoprotective iridoid glycosides from the roots of Rehmannia glutinosa.
AID1594770Hepatoprotective activity in human HepG2 cells assessed as inhibition of APAP-induced cell damage at 10 uM by MTT assay relative to control2019Journal of natural products, 06-28, Volume: 82, Issue:6
Rearranged Clerodane Diterpenoids from the Stems of Tinospora baenzigeri.
AID376265Hepatoprotective activity in rat WB-F344 cells assessed as inhibition of D-galactosamine-induced toxicity at 0.1 mM by MTT method relative to control2006Journal of natural products, Apr, Volume: 69, Issue:4
Hepatoprotective sesquiterpene glycosides from Sarcandra glabra.
AID376266Cytotoxicity against rat WB-F344 cells assessed as cell survival rate at 0.1 mM by MTT method relative to control2006Journal of natural products, Apr, Volume: 69, Issue:4
Hepatoprotective sesquiterpene glycosides from Sarcandra glabra.
AID1317004Hepatoprotective activity against N-acetyl-p-aminophenol-induced cell injury in human HepG2 cells assessed as cell survival at 10 uM after 48 hrs by MTT assay (Rvb = 39.87%)2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Six new compounds from Atractylodes lancea and their hepatoprotective activities.
AID1056619Hepatoprotective activity in human HL-7702 cells assessed as inhibition of D-galactosamine-induced toxicity at 1x10'-5 M by MTT assay relative to control2013Journal of natural products, Dec-27, Volume: 76, Issue:12
Dibenzoyl and isoflavonoid glycosides from Sophora flavescens: inhibition of the cytotoxic effect of D-galactosamine on human hepatocyte HL-7702.
AID674369Hepatoprotective activity in rat WB-F344 cells assessed as inhibition of DL-Galactosamine-induced toxicity at 10 uM incubated for 1 hr prior to DL-Galactosamine-challenge measured after 24 hrs by MTT assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Alkaloids from the root of Isatis indigotica.
AID1616508Hepatoprotective activity against APAP-induced cytotoxicity in human HepG2 cells assessed as cell survival rate at 10 uM incubated for 48 hrs by MTT assay relative to control2019Journal of natural products, 10-25, Volume: 82, Issue:10
Hepatoprotective Tetrahydrobenzocyclooctabenzofuranone Lignans from
AID1376915Cytoprotection against 8 mM acetaminophen-induced human HepG2 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay (Rvb = 0 +/- 2%)2017Journal of natural products, 06-23, Volume: 80, Issue:6
Bioactive Glycosides from the Twigs of Litsea cubeba.
AID706700Hepatoprotective activity in D-galactosamine-treated human HL7702 cells assessed as survival rate at 10 uM preincubated for 1 hr prior to D-galactosamine challenge measured after 24 hrs by MTT assay relative to normal cell2012Journal of natural products, Sep-28, Volume: 75, Issue:9
Hepatoprotective iridoid glycosides from the roots of Rehmannia glutinosa.
AID1301504Hepatoprotective activity against APAP-induced toxicity in human HepG2 cells assessed as cell survival rate at 10 uM incubated for 48 hrs by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii.
AID611889Hepatoprotective activity in rat WB-F344 cells assessed as inhibition of D-galactosamine-induced cell damage at 10 uM treated 1 hr before D-galactosamine challenge after 24 hrs by MTT assay2011Journal of natural products, Jun-24, Volume: 74, Issue:6
Bioactive neolignans and lignans from the bark of Machilus robusta.
AID1761891Hepatoprotective activity against APAP-induced toxicity in human HepG2 cells assessed as cell survival rate at 10 uM after 48 hrs by MTT assay (Rvb = 23 %)2021Journal of natural products, 03-26, Volume: 84, Issue:3
Hepatoprotective Glucosyloxybenzyl 2-Hydroxy-2-isobutylsuccinates from
AID1055751Hepatoprotective activity in human HL-7702 cells assessed as inhibition of D-galactosamine-induced cell toxicity incubated for 1 hr prior to D-galactosamine-challenge measured after 24 hrs by MTT assay relative to control2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Hepatoprotective prenylaromadendrane-type diterpenes from the gum resin of Boswellia carterii.
AID468192Hepatoprotective activity in rat WB-F344 cells assessed as inhibition of D-galactosamine-induced cytotoxicity at 100 uM treated 1 hr before D-galactosamine challenge after 24 hrs by MTT assay2009Journal of natural products, Dec, Volume: 72, Issue:12
Chemical constituents of the bark of Machilus wangchiana and their biological activities.
AID1410154Hepatoprotective activity against APAP-induced toxicity in human HepG2 cells assessed as cell survival rate at 10 uM after 48 hrs by MTT assay relative to control2018Journal of natural products, 04-27, Volume: 81, Issue:4
Hepatoprotective Dibenzocyclooctadiene and Tetrahydrobenzocyclooctabenzofuranone Lignans from Kadsura longipedunculata.
AID465835Cytotoxicity against rat WB-F344 cells assessed as cell survival rate after 1 hr at 100 uM by MTT assay2010Journal of natural products, Feb-26, Volume: 73, Issue:2
Hepatoprotective constituents from the roots and stems of Erycibe hainanesis.
AID1423292Hepatoprotective activity in human HepG2 cells assessed as inhibition of paracetamol-induced reduction in cell viability at 10 uM pretreated for 1 hr followed by paracetamol addition after 24 hrs by MTT assay relative to control2018Journal of natural products, 11-26, Volume: 81, Issue:11
Methylated Polycyclic Polyprenylated Acylphloroglucinol Derivatives from Hypericum ascyron.
AID1761890Hepatoprotective activity against D-GalN-induced toxicity in human HL-7702 cells assessed as cell survival rate at 10 uM preincubated for 48 hrs followed by D-GalN stimulation for 8 hrs by MTT assay (Rvb = 33 %)2021Journal of natural products, 03-26, Volume: 84, Issue:3
Hepatoprotective Glucosyloxybenzyl 2-Hydroxy-2-isobutylsuccinates from
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (126)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's47 (37.30)29.6817
2010's61 (48.41)24.3611
2020's18 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.95 (24.57)
Research Supply Index4.95 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index54.53 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (37.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (11.11%)5.53%
Reviews8 (6.35%)6.00%
Case Studies1 (0.79%)4.05%
Observational0 (0.00%)0.25%
Other103 (81.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]